N-丁基-4-氯-3-硝基苯甲酰胺 | 59320-12-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-丁基-4-氯-3-硝基苯甲酰胺
• 英文名称: N-butyl-(4-chloro-3-nitrophenyl)carboxamide
• 英文别名: N-butyl-4-chloro-3-nitrobenzamide；(N-Butyl)-4-chlor-3-nitrobenzoesaeureamid
• CAS: 59320-12-6
• 化学式: C₁₁H₁₃ClN₂O₃
• mdl: MFCD01182368
• 分子量: 256.689
• InChiKey: YVBGUSUYCUSCBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-丁基-4-氯-3-硝基苯甲酰胺 在 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 6.0h， 生成 Methyl 2-[4-[2-amino-4-(butylcarbamoyl)phenoxy]-3-methoxyphenyl]acetate
  参考文献：
  名称：

  Optimization of phenylacetic acid derivatives for CRTH2 and DP selective antagonism

  摘要：

  We have previously reported that optimization of a series of phenylacetic acid derivatives led to the discovery of CRTH2 and DP dual antagonists, such as AMG 009 and AMG 853. During the optimization process, we discovered that minor structural modifications also afforded potent and selective CRTH2 or DP antagonists. Here we report the structure-activity relationship that led to the discovery of selective CRTH2 antagonists such as 2 and 17, and selective DP antagonists, such as 4 and 5. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.123
• 作为产物：
  描述：

  正丁胺 、 4-氯-3-硝基苯甲酸 在 N-羟基丁二酰亚胺 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.33h， 以91%的产率得到N-丁基-4-氯-3-硝基苯甲酰胺
  参考文献：
  名称：

  三苯基膦介导的2-硝基联苯的还原环化反应：咔唑的实用便捷合成方法

  摘要：

  描述了使用Cadogan反应的新型修饰从相应的2-硝基联苯衍生物合成一系列取代的咔唑。2-硝基联苯的环化是通过在适当的溶剂中使用稍微过量的三苯膦通过硝基的还原性脱氧来实现的。我们已经观察到在这些条件下温度对转化率的依赖性，较高沸点的溶剂可在一系列底物上提供较高的收率。新的反应条件非常简单易行，可以耐受各种官能团，并在不存在不需要的副产物的情况下生成咔唑产物。

  DOI：

  10.1021/jo0503299

文献信息

• [EN] PHENYL ACETIC ACID DERIVATIVES AS INFLAMMATION MODULATORS<br/>[FR] DÉRIVÉS DE L'ACIDE PHÉNYLACÉTIQUE UTILES COMME MODULATEURS DE L'INFLAMMATION
  申请人：AMGEN INC

  公开号：WO2009085177A1

  公开（公告）日：2009-07-09

  Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives of formula I wherein R1 is alkyl or cycloalkyl; R2 is halo, alky I, haloalkyl, alkoxy, haloalkoxy or cycloalkyl; and X is chloro or fluoro.

  提供了在治疗炎症性和免疫相关疾病和症状中有用的化合物、药物组合物和方法。具体来说，本发明提供了调节涉及特应性疾病、炎症症状和癌症中的蛋白质功能和/或表达的化合物。所述化合物为式I的羧酸衍生物，其中R1为烷基或环烷基；R2为卤、烷基、卤代烷基、烷氧基、卤代烷氧基或环烷基；X为氯或氟。
• Discovery of AMG 853, a CRTH2 and DP Dual Antagonist
  作者：Jiwen Liu、An-Rong Li、Yingcai Wang、Mike G. Johnson、Yongli Su、Wang Shen、Xuemei Wang、Sarah Lively、Matthew Brown、SuJen Lai、Felix Gonzalez Lopez De Turiso、Qingge Xu、Bettina Van Lengerich、Mike Schmitt、Zice Fu、Ying Sun、Shanna Lawlis、Lisa Seitz、Jay Danao、Jill Wait、Qiuping Ye、Hua Lucy Tang、Mark Grillo、Tassie L. Collins、Timothy J. Sullivan、Julio C. Medina

  DOI：10.1021/ml1002234

  日期：2011.5.12

  Prostaglandin D2 (PGD2) plays a key role in mediating allergic reactions seen in asthma, allergic rhinitis, and atopic dermatitis. PGD2 exerts its activity through two G protein-coupled receptors (GPCRs), prostanoid D receptor (DP or DP1), and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2 or DP2). We report the optimization of a series of phenylacetic acid derivatives in an

  前列腺素 D 2 (PGD 2 ) 在介导哮喘、过敏性鼻炎和特应性皮炎中所见的过敏反应中起关键作用。PGD 2通过两种 G 蛋白偶联受体 (GPCR)、前列腺素 D 受体（DP 或 DP 1）和在 Th2 细胞上表达的趋化受体同源分子（CRTH2 或 DP 2）发挥其活性。我们报告了一系列苯乙酸衍生物的优化，以努力提高 AMG 009 对 DP 和 CRTH2 的双重活性。这些努力导致 AMG 853 (2-(4-(4-( tert-丁基氨基甲酰基）-2-（2-氯-4-环丙基苯基磺酰氨基）苯氧基）-5-氯-2-氟苯基）乙酸），正在对哮喘的人体临床试验进行评估。
• Pd-Catalyzed Deoxygenation of Mandelate Esters
  作者：Jacqueline E. Milne、Jerry A. Murry、Anthony King、Robert D. Larsen

  DOI：10.1021/jo8021499

  日期：2009.1.2

  A new approach to the synthesis of phenylacetic acids and esters has been developed via the palladium-catalyzed deoxygenation of mandelate esters.

  通过钯催化的扁桃酸酯的脱氧反应，已开发出一种新的合成苯乙酸和酯的方法。
• Asthma and allergic inflammation modulators
  申请人：Fu Zice

  公开号：US20080085891A1

  公开（公告）日：2008-04-10

  Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.

  本发明提供了在治疗炎症和免疫相关疾病和病况方面有用的化合物、制药组合物和方法。特别是，本发明提供了调节参与过敏性疾病、炎症病况和癌症的蛋白质的功能和/或表达的化合物。所述化合物为羧酸衍生物。
• Discovery and optimization of CRTH2 and DP dual antagonists
  作者：Jiwen Liu、Zice Fu、Yingcai Wang、Mike Schmitt、Alan Huang、Derek Marshall、George Tonn、Lisa Seitz、Tim Sullivan、H. Lucy Tang、Tassie Collins、Julio Medina

  DOI：10.1016/j.bmcl.2009.09.052

  日期：2009.11

  A series of phenylacetic acid derivatives was discovered as CRTH2 antagonists. Modification of the series led to compounds that are also antagonists of DP. Since activation of CRTH2 and DP are believed to play key roles in mediating responses of asthma and other immune diseases, this series was optimized to increase the dual antagonistic activities and improve pharmacokinetic properties. These efforts led to selection of AMG 009 as a clinical candidate. (C) 2009 Elsevier Ltd. All rights reserved.